Compare Repligen Corporation Common Stock (RGEN) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Wolfspeed Inc — how do they compare? Repligen Corporation Common Stock trades at $180.35 (market cap $11.31B), while Wolfspeed Inc trades at $23.93 (market cap $1.30B). The key difference: Repligen Corporation Common Stock is far larger — about 8.7× Wolfspeed Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Wolfspeed Inc for 20 Days on average.
| RGEN | WOLF | |
|---|---|---|
Market Cap | $11.31B | $1.30B |
Volume | 1,216,919 | 5,457,662 |
Sector | Health | Technology |
52-Week High | $194.57 | $73.68 |
52-Week Low | $102.87 | $14.80 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $11.20B | $2.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Wolfspeed (WOLF) trades at $28.67, up 2.25% today, amid mixed technical signals with a bearish overall trend but bullish oscillators. The company shows severe profitability challenges with a -212.41% net income margin in 2025, though 2026 projections indicate potential breakeven. Recent news highlights expansion of 200mm silicon carbide technology and ongoing investor investigations, creating a volatile sentiment environment.
The stock presents high-risk speculation with analyst consensus target of $54.32 suggesting significant upside, but current fundamentals reflect substantial operational losses and negative margins. Investment appeal hinges on successful execution of silicon carbide growth strategy and achieving projected 2026 profitability, though legal investigations and competitive pressures remain material risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
